Recent Update,It is illegal to make or sell compounded semaglutide

The availability of semaglutide from compounding pharmacies has been a significant topic of discussion and concern, particularly following the semaglutide shortage. For individuals seeking this medication, understanding the current status and legalities surrounding compounded semaglutide is crucial. Recent developments, including the FDA's declaration that the semaglutide shortage is over on February 21, 2025, have reshaped the landscape for compounding pharmacies.

Historically, compounding pharmacies played a vital role in ensuring access to semaglutide when the branded versions, such as Ozempic and Wegovy, faced national shortages. These pharmacies began making compounded semaglutide injections to bridge the gap, offering a custom-made alternative containing the same active ingredient, semaglutide. This practice was initially permitted under specific FDA guidelines related to drug shortages.

However, with the resolution of the semaglutide shortage on Feb 21, 2025, the regulatory environment for compounded semaglutide has shifted. The FDA has clarified its policies, leading to restrictions on the production and sale of compounded versions of GLP-1 medications. Many compounding pharmacies are now no longer allowed to make cheaper versions of semaglutide. Specifically, after May 22, 2025, compounding pharmacies can no longer make and sell semaglutide injections in the same capacity as before. This means that it is illegal to make or sell compounded semaglutide outside of very specific, limited circumstances.

The FDA's updated guidance aims to ensure that patients have access to FDA-approved medications. Consequently, the era of widespread availability of compounded semaglutide from compounding pharmacies is drawing to a close. While some 503A pharmacies can still compound semaglutide for now, a wind-down period of 60 or 90 days has been implemented depending on the type of compounding facility. This transition aims to avoid unnecessary disruption for patients and pharmacies.

For those who previously relied on or were considering buy compounded semaglutide from online pharmacies, it is important to be aware of these changes. While some telehealth platforms like Hims & Hers have confirmed they will continue to offer compounded semaglutide to eligible patients, this may be subject to evolving regulations and patient-specific exceptions.

It's essential to understand that compounded semaglutide is not FDA-approved, unlike Ozempic and Wegovy. While compounded semaglutide can be dispensed legally under certain conditions, the stricter regulatory environment now means that obtaining it may be more challenging. The availability of the branded versions nationwide is a key factor influencing these changes.

The question of whether compounded semaglutide is still available requires a nuanced answer. While direct production and sale by many compounding pharmacies are being phased out, the precise legal standing and availability can depend on the specific compounding pharmacy, state regulations, and the nature of the prescription. Patients seeking semaglutide should consult with their healthcare provider to discuss the most appropriate and legally compliant options available to them, which may include FDA-approved semaglutide products or other therapeutic alternatives. The focus is shifting back towards FDA-approved semaglutide and away from compounding for broad distribution.